Rejoyn, a software app developed by Otsuka Pharmaceutical and Click Therapeutics, has received FDA clearance as the first prescription digital therapeutic for treating major depressive disorder. The app offers cognitive behavioral therapy lessons, exercises, and reminders in a digital format, intended for use three times weekly for six weeks. Clinical trials showed a trend favoring continued improvement in symptoms. Rejoyn does not replace drug therapy but is used as an adjunct to antidepressant medication. Unlike other digital therapeutics that struggled with reimbursement, Rejoyn is backed by a large company and expected to be available for download this summer, pending payer coverage.
Source link
FDA Clears the First Digital Therapeutic for Depression, But Will Payers Cover It?
